A post-hoc analysis to assess prognostic factors was performed with the use of patients with EGFR mutations ( exon 19 deletion , L858R , G719X , and L861Q ) who were treated with gefitinib in the NEJ002 study , which compared gefitinib with carboplatin-paclitaxel as the first-line therapy .